CD3
Cluster of differentiation 3
CD3 (cluster of differentiation 3) is a protein complex and T cell co-receptor that is involved in activating both the cytotoxic T cell (CD8+ naive T cells) and T helper cells (CD4+ naive T cells). It is composed of four distinct chains. In mammals, the complex contains a CD3γ chain, a CD3δ chain, and two CD3ε chains. These chains associate with the T-cell receptor (TCR) and the CD3-zeta (ζ-chain) to generate an activation signal in T lymphocytes. The TCR, CD3-zeta, and the other CD3 molecules together constitute the TCR complex.
All Product Categories
-
CD3 Related Products (108)
Related Products (108)
-
Antibodies (20)
-
Ebribafusp alfa
0 ImagesCat. No.: HY-P990955CAS No.: 2839652-75-2Synonyms: ADX-097Ebribafusp alfa (ADX-097) comprising a humanized anti-C3d monoclonal antibody linked to two moieties of the first five consensus repeats of factor H (fH1-5). Ebribafusp alfa binds C3d and related fragments, catalyzes AP convertase dissociation, acts as a factor I co-factor for C3b cleavage, and delivers fH1-5 moieties to C3d-deposited tissues for local complement inhibition without systemic blockade. Ebribafusp alfa reduces glomerular C3 deposition, proteinuria, urine albumin-creatinine ratios, and urine soluble C5b-9 levels, preserves podocyte foot-process architecture, inhibits skin complement activation, and localizes to UVB-damaged primate skin. Ebribafusp alfa can be used for the research of membranous nephropathy, bullous pemphigoid, discoid lupus erythematosus, C3 glomerulopathy, IgA nephropathy, and lupus nephritis.
-
Lck-IN-5
0 ImagesLck-IN-5 (example C10) is a potent and selective lymphocyte-specific protein tyrosine kinase (LCK) inhibitor. Lck-IN-5 selectively disrupts the interaction between the SH3 domain of LCK and the RK motif of CD3ε, thereby impairing LCK recruitment to the TCR. Lck-IN-5 modulates the activity of CD3ε-containing CAR and TRuC T cells, attenuating cytokine production and promoting a central-memory-like phenotype associated with enhanced persistence. Lck-IN-5 can be used for autoimmune diseases and graft-versus-host disease research.
-
Mipletamig
0 ImagesSynonyms: APVO-436Mipletamig (APVO-436) is a bispecific CD123 x CD3 monoclonal antibody. Mipletamig simultaneously binds to both CD3-expressing T cells and CD123-expressing cancer cells, thereby crosslinking CD123-expressing tumor cells and cytotoxic T lymphocytes (CTLs). This results in the activation and proliferation of T-cells and causes CTL-mediated cell lysis of CD123-expressing tumor cells. Mipletamig can be used for the study of acute myeloid leukemia (AML).
-
Ciduvectamig
0 ImagesCat. No.: HY-P990692CAS No.: 2412587-62-1Synonyms: JNJ-70218902; JNJ-902
-
HPN536
0 ImagesCat. No.: HY-P991088Purity: 99.00%HPN536 is a trispecific, T-cell-activating protein-based construct, which binds to mesothelin-expressing tumor cells, CD3ε on T cells, and to serum albumin. HPN536 specifically redirects T cells for potent redirected lysis of mesothelin-expressing cancer cells with concomitant T-cell activation.
-
Varzutamig
0 ImagesCat. No.: HY-P992140CAS No.: 3064817-31-5Varzutamig is a bispecific antibody targeting CD3E/ALB/EGFR.
-
Anafiltamig
0 ImagesCat. No.: HY-P991671CAS No.: 3009026-69-8Synonyms: JNJ-80948543Anafiltamig is a trivalent monoclonal antibody inhibitor targeting CD79B, CD3E and MS4A1. Anafiltamig consists of a humanized IgG1κ anti-CD79B arm and a bispecific scFv-based arm targeting CD3E and MS4A1. Anafiltamig simultaneously bridges T and B cells, activating T cells and specifically killing B cell tumors. Anafiltamig can be used for B cell malignancies such as non-Hodgkin lymphoma research.
-
Lumivatamig
0 ImagesCat. No.: HY-P991700CAS No.: 3035406-55-1Lumivatamig is an H-γ1_L-κ-scFvhl dimer-type bispecific antibody targeting CLDN18.2 & CD3E.
-
AFM15
0 ImagesCat. No.: HY-P991552AFM15 is a humanized monoclonal antibody inhibitor targeting CD3E. AFM15 can be used to study metabolic and immune system diseases, such as type 1 diabetes and inflammatory bowel disease (IBD).
-
STI-8811 Antibody
0 ImagesCat. No.: HY-P991877STI-8811 Antibody is an anti-human BCMA antibody. STI-8811 Antibody can generate antibody drug conjugate (ADC) (STI-8811) with an auristatin derivative, Duostatin 5 (HY-145149). STI-8811 Antibody can be used for the study of multiple myeloma.
-
Imvotamab
0 ImagesCat. No.: HY-P99660CAS No.: 2573121-53-4Synonyms: IGM-2323Imvotamab (IGM-2323) is a CD20 and CD3 bispecific IGM antibody with dual action mechanism. Imvotamab is used to induce physiological T cell activation to prevent over-stimulation and subsequent down-regulation of immune function. Imvotamab can be used for the study of B-cell malignant tumors, multiple myeloma (MM) and non-Hodgkin's lymphoma (NHL).
-
MEDI-2228 Antibody
0 ImagesCat. No.: HY-P991876MEDI-2228 Antibody is an anti-human BCMA antibody that preferentially binds to membrane-bound BCMA versus soluble BCMA. MEDI-2228 Antibody can generate antibody drug conjugate (ADC) (MEDI 2228) with a pyrrolobenzodiazepine (PBD) dimer. MEDI-2228 Antibody can be used for the study of multiple myeloma.
-
ST1072
0 ImagesCat. No.: HY-133488CAS No.: 1402703-50-7ST1072 is an inhibitor of CerS4 and CerS6. ST1072 preferentially inhibits CerS6 over CerS4, and reduces the production of C16 ceramide. ST1072 impairs TCR-mediated N-RAS activation, ERK signaling pathway, and the colocalization of CD3/PKCθ. ST1072 decreases the production of IFN-γ as well as the migration of donor cells to target organs. ST1072 regulates immune cell populations and the expression of co-stimulatory molecules. ST1072 can be used in research related to colon cancer, cervical cancer, graft-versus-host disease, and hematologic malignancies.
-
MS133
0 ImagesCat. No.: HY-P991463
-
TCR-IN-2
0 ImagesCat. No.: HY-180609CAS No.: 2375043-73-3
-
Anti-Mouse CD3E Antibody (500A2)
0 ImagesCat. No.: HY-P992061Anti-Mouse CD3E Antibody (500A2) is an antibody targeting mouse CD3ε, which specifically binds to the region on CD3ε adjacent to the T cell receptor binding site. Anti-Mouse CD3E Antibody (500A2) triggers functional signal transduction in immature T cells and activates naive T cells. When cross-linked, Anti-Mouse CD3E Antibody (500A2) induces a rapid, robust and transient increase in cytoplasmic calcium concentration, acting as a potent calcium flux inducer. Anti-Mouse CD3E Antibody (500A2) is suitable for multiple experimental techniques such as flow cytometry, immunoprecipitation and EMARS reactions. It can be used to detect CD3E expression on thymocytes, mature T lymphocytes and NK-T cells from different mouse strains, or to identify membrane cluster components of the TCR complex, and shows no cross-reactivity with rat leukocytes.
-
Maydispenoid B
0 ImagesCat. No.: HY-N10446CAS No.: 3024647-69-3Maydispenoid B is a potent immunosuppressor. Maydispenoid B can inhibit anti-CD3/anti-CD28 mAbs activated and lipopolysaccharide activated murine splenocyte proliferation.
